{"id":"NCT03945175","sponsor":"NYU Langone Health","briefTitle":"Study of the Duration and Efficacy of MYDAYIS on Adult ADHD Symptoms and Executive Function Throughout the Day Into the Early Evening","officialTitle":"Study of the Duration and Efficacy of MYDAYIS on Adult ADHD Symptoms and Executive Function Throughout the Day Into the Early Evening","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-07-15","primaryCompletion":"2022-05-11","completion":"2022-05-11","firstPosted":"2019-05-10","resultsPosted":"2023-06-29","lastUpdate":"2024-03-08"},"enrollment":52,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Attention Deficit-Hyperactivity"],"interventions":[{"type":"DRUG","name":"MYDAYIS","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Treatment","type":"EXPERIMENTAL"}],"summary":"Attention-deficit/hyperactivity disorder (ADHD) is a neuropsychiatric disorder characterized by problems with sustaining attention, organization, planning, procrastination, daydreaming, restlessness, impulsivity and hyperactivity.This is an outpatient study for subjects between the ages of 18-60, who have an Attention deficit hyperactivity disorder (ADHD) diagnosis meeting all inclusion criteria and not meeting any of the exclusion criteria.","primaryOutcome":{"measure":"Adult ADHD Investigator Symptom Rating Scale (AISRS) Score at End of Placebo Lead-In","timeFrame":"Week 2 (End of Placebo Lead-In)","effectByArm":[{"arm":"Placebo, Then Mydayis","deltaMin":37.2,"sd":11.4}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":2,"exclusionCount":7},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":18},"commonTop":["Headache","Tachycardia","Dry Mouth","Insomnia","Cough"]}}